Evidence map›Paper›PMID 41710645›Full record

ArticleCase reports in oncology

Successful Plasma Exchange and Steroid Maintenance Therapy for Severe Pembrolizumab-Induced Polyradiculoneuritis in Lung Cancer: A Case Report.

Yuichi Sakamori, Kentaro Hamada, Ken Yamada, Yuki Kawamura, Hirofumi Yamashita, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Kizuku Watanabe, Tatsuyoshi Ikeue

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuichi SakamoriDepartment of Respiratory Medicine, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Kentaro HamadaDepartment of Respiratory Medicine, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Ken YamadaDepartment of Neurology, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Yuki KawamuraDepartment of Neurology, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Hirofumi YamashitaDepartment of Neurology, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Hiroaki KawachiDepartment of Respiratory Medicine, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Akari FukaoDepartment of Respiratory Medicine, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Satoshi TerashitaDepartment of Respiratory Medicine, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Kizuku WatanabeDepartment of Respiratory Medicine, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.
Tatsuyoshi IkeueDepartment of Respiratory Medicine, Japan Red Cross Wakayama Medical Center, Wakayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Neurological immune-related adverse events (n-irAEs) caused by immune checkpoint inhibitors are rare but can be life-threatening. Case Presentation: A 43-year-old man with stage IVB squamous cell carcinoma of the lung developed progressive polyradiculoneuropathy 180 days after the first pembrolizumab administration. Initial treatments with high-dose corticosteroids and intravenous immunoglobulin were ineffective. Cerebrospinal fluid (CSF) analysis revealed albuminocytologic dissociation, and magnetic resonance imaging (MRI) revealed cervical nerve root hypertrophy. Plasma exchange (PE) was initiated along with steroid maintenance, resulting in gradual neurological recovery, as evidenced by improvements in the MRC score (from 32 to 56, on a scale from 0 to 60, with higher scores indicating greater muscle strength) and resolution of MRI abnormalities. Tumor control was sustained throughout the treatment. Conclusion: This case highlights the potential efficacy of combining PE and steroid maintenance therapy in managing severe, refractory n-irAEs without compromising oncologic outcomes.

Indexed as

Immune checkpoint inhibitorPembrolizumabPlasma exchangePolyradiculoneuritisSteroid maintenance

Identifiers

PMID41710645
PMCPMC12912767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.